Early Clinical Performance of an Adaptive Self-Assembling Barrier Scaffold in Nonhealing Chronic Wounds

A Review of Six Cases

Daniel Kapp, MD, PA; Laura Pfendler, PT, DPT, CWS; Lou D'Oro, MD; Randall Wolcott, MD


Wounds. 2022;34(1):20-30. 

In This Article


In this study, aSABS had a marked effect on wound healing by interrupting the stalled inflammatory phase, reducing the bioburden of infected wound tissue, and stimulating the progression of the wound through the proper biological sequence of repair. Also noteworthy was the fast pace of healing (3 weeks in some cases), with only weekly clinic visits and reapplication. Even in patients with considerable systemic comorbidities, use of aSABS resulted in the healing of wounds that had been persistently inflamed and infected and for which other advanced wound products and surgical debridement had been unsuccessful. The clinical observations noted in these cases can be attributed to the multimodal mechanism of aSABS, which includes creating a protective, bioresorbable barrier that conforms naturally to diverse wound beds, modulates inflammation, reduces bioburden, and has a nanofiber network that supports tissue repair, providing utility throughout all stages of wound healing. It was also believed that aSABS improved patients' quality of life and the at-home burden of wound care for both patients and their caretakers. In addition to potentially providing a favorable effect on patient morbidity and mortality in wound management, broader adoption of this advanced product may reduce the burden on the currently resource-constrained health care system by providing a better option for managing chronic, refractory, or otherwise challenging wounds. A clinical trial comparing the performance and cost-effectiveness of aSABS with currently existing therapies is warranted.